BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Thales Nanotechnology, Inc. Announces the Launch of H-Cube Midi(TM), its Next Generation Hydrogenation Technology Product Applicable for Process Development


10/9/2007 10:27:28 AM

BUDAPEST, Hungary, PRINCETON, New Jersey and LONDON, October 8 /PRNewswire/ -- ThalesNano Inc. announced today that it has launched the latest of its Cube(TM) flow reactor series, H-Cube Midi(TM). This novel product is now commercially available and validated with several important chemistry applications.

The H-Cube Midi(TM) is designed to fulfill the requirements of process scale flow hydrogenation. Based upon the current H-Cube(R) technology platform, the H-Cube Midi(TM) is designed to increase the capacity of the present H-Cube(R) up to kg quantities per day without compromising efficiency and safety.

Dr. Laszlo Urge, CEO of ThalesNano commented: "H-Cube Midi(TM) was designed in response to increasing customer needs to be able to scale up reactions optimized on H-Cube(R). Several pharmaceutical companies have adopted H-Cube(R) as the first choice for hydrogenation in discovery. As compounds move from discovery to development, there is a need to increase the scale up to kg levels as fast as possible. The H-Cube Midi(TM) allows the optimization and transition from mg scale to kg levels to be performed within a day. The increase in productivity and the savings in cost and time are expected to be significant for those R&D organizations who have adopted this technology."

"The launch of this new product underlines that we are executing a complex strategy and building a product portfolio in the flow chemistry area. Our product development strategy is designed to provide integrated continuous flow solutions from discovery to full scale production and could help solve some of the bottlenecks in the pharmaceutical and chemical industries" stated Dr. Ferenc Darvas, President and Chairman at ThalesNano.

For more information please refer to ThalesNano's website at http://www.thalesnano.com/

About ThalesNano:

ThalesNano is a technology-intensive company that provides chemical Solutions in discovery, process development and production for pharmaceutical And chemical companies. The Company specializes in developing and providing microscale flow instruments for chemistry, by exploiting the benefits of combining micro- and meso-fluidics and nanotechnology with flow chemistry.

The award winning development, H-Cube(TM), has been recognized as one of the 100 most technologically significant and innovative new products of 2005 by R&D Magazine and is the first in a new wave of continuous-flow hydrogenation reactors. Utilizing water electrolysis to generate hydrogen, with a catalyst cartridge system and with a continuous-flow reactor, the shoe-box sized H-Cube(TM) makes hydrogenation convenient, more efficient and less hazardous. With this equipment, reactions that are extremely challenging to carry out with traditional methods can be performed. These products are already on the market and utilized by 18 of the top 20 pharmaceutical companies in the world.

titkarsag@thalesnano.com

CONTACT: Contact: Laszlo Urge, CEO, e-mail: titkarsag@thalesnano.com,
Telephone: +36-1-880-8500



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES